芦可替尼乳膏(Opzelura)上市了吗,在哪里能买到？

Ruxolitinib cream is a Janus kinase (JAK) inhibitor, whose English name is Opzelura, and can be used for mild to moderate atopic dermatitis (AD) in non-immunocompromised patients over 12 years old. (Opzelura) is currently not available in the country and needs to be purchased abroad. According to data, the price of ruxolitinib cream available overseas is more than US$3,000. Today we will learn more about whether ruxolitinib cream (Opzelura) is on the market and where can I buy it?

Ruxolitinib cream (Opzelura) launched

Ruxolitinib cream (Opzelura) was developed by Incyte Biopharmaceutical Company in the United States. It was approved by the U.S. FDA for marketing on July 18, 2022. It is used for topical treatment of adults and adolescent and adult patients 12 years old and above with non-segmental vitiligo. On September 21, 2021, the U.S. Food and Drug Administration (FDA) approved ruxolitinib cream for the short-term and non-continuous long-term treatment of patients over 12 years old with mild to moderate atopic dermatitis (AD). The marketing application for ruxolitinib cream to treat atopic dermatitis (AD) has obtained FDA priority review status.

In the treatment of vitiligo, TRuE-V clinical trials include two phase III studies, TRuE-V1 and TRuE-V2. The positive results of the phase III studies show that vitiligo patients treated with ruxolitinib cream have significant improvements in facial and systemic pigment recovery. In October 2021, ruxolitinib cream has been approved for marketing in Europe for the treatment of non-segmental vitiligo with facial involvement in adolescents and adults. At present, there is no news about ruxolitinib cream (Opzelura) being launched in China, and patients still need to wait patiently.

Where to buy ruxolitinib cream (Opzelura)

Ruxolitinib cream (Opzelura) is not available in China and is not available in domestic hospital pharmacies. Patients in need can go abroad to purchase it. However, the price of ruxolitinib cream (Opzelura) available overseas is about US$3,000. It is a long journey, expensive and risky, and is not suitable for long-term use by patients. Patients can also obtain ruxolitinib cream (Opzelura) marketed overseas through domestic professional overseas medical service institutions. It can be directly mailed to their homes from overseas, which ensures that the drug is genuine and affordable. They can buy this product without going abroad, which can reduce the financial burden on patients.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: